Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Dec 20;11(3):880-882.
doi: 10.1159/000495032. eCollection 2018 Sep-Dec.

Case Report: Oxaliplatin-Induced Immune-Mediated Thrombocytopenia

Elizabeth Pan  1 , Eric Hsieh  1 , Caroline Piatek  2
Affiliations
Case Reports

Case Report: Oxaliplatin-Induced Immune-Mediated Thrombocytopenia

Elizabeth Pan et al. Case Rep Oncol. .

Abstract

Thrombocytopenia is a frequent complication of cancer may be due to a variety of causes including malignancy itself, acute disease processes, or cancer therapy. Systemic cancer therapy is the most common cause of thrombocytopenia in cancer patients observed nearly two-thirds of patients with solid tumors. Thrombocytopenia with traditional chemotherapy agents is most frequently the result of megakaryocyte cytotoxicity. Oxaliplatin is a platinum derivative commonly used in gastrointestinal malignancies and is associated with drug-induced immune thrombocytopenia.

Keywords: Adenocarcinoma; Oxaliplatin; Thrombocytopenia.

PubMed Disclaimer

References

    1. Jardim DL, Rodrigues CA, Novis YA, Rocha VG, Hoff PM. Oxaliplatin-related thrombocytopenia. Ann Oncol. 2012 Aug;23((8)):1937–42. - PubMed
    1. Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT. Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol. 2010 Mar;3((1)):12. - PMC - PubMed
    1. Taleghani BM, Meyer O, Fontana S, Ahrens N, Novak U, Borner MM, et al. Oxaliplatin-induced immune pancytopenia. Transfusion. 2005 May;45((5)):704–8. - PubMed
    1. Curtis BR, Kaliszewski J, Marques MB, Saif MW, Nabelle L, Blank J, et al. Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin. Am J Hematol. 2006 Mar;81((3)):193–8. - PubMed
    1. Ohta S, Cho Y, Oshima S, Hosoya O, Juni K, Kojima H. Oxaliplatin-induced acute-onset thrombocytopenia and hemorrhage: case report and review of the literature. Oncol Lett. 2012 Jun;3((6)):1297–300. - PMC - PubMed

Publication types